KIIL HARRY SKIP sold $337K of MDT

KIIL HARRY SKIP (EVP & President Cardiovascular) sold 4,189 shares of Medtronic plc (MDT) at an average of $80.44 ($80.44–$80.45, $0.34M total) across 2 trades on 2026-06-08.

Original reporting
SEC EDGAR · KIIL HARRY SKIP
Published Jun 9, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDT
Neutral
medium confidence
Mentioned
$MDT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with any concurrent company-specific catalysts, but this filing alone does not provide new operational or financial guidance.

02

Market read

A primary-source insider sale disclosure for MDT; sentiment impact is likely limited absent other negative news.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs; without additional context, directional inference is weak.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-09; sale executed 2026-06-08

Background

The article is an SEC Form 4 insider transaction disclosure from Medtronic plc, reporting an open-market sale by a cardiovascular business executive.

Company-level read

Ticker impact

$MDTNeutralMedium confidence
Context

Medtronic insider KIIL HARRY SKIP (EVP & President, Cardiovascular) sold 4,189 shares in open-market transactions on 2026-06-08.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other negative company news.

Evidence & confidence

The filing is a primary-source insider transaction, but it is not tied to a 10b5-1 plan and is not large enough (relative to MDT) to imply a fundamental change by itself.

Market effects

Minimal—single-company insider sale without accompanying operational/regulatory updates.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan, some traders may interpret it as a more meaningful near-term caution signal than typical routine selling.

Key entities

  • Medtronic plc

    MDT, the company whose shares were sold by an executive insider.

  • KIIL HARRY SKIP

    EVP & President, Cardiovascular; reported open-market sale of 4,189 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.